Aadi Bioscience Inc. (AADI)
3.25
0.25 (8.51%)
At close: Jan 15, 2025, 3:59 PM
3.20
-1.54%
After-hours Jan 15, 2025, 06:55 PM EST
undefined% (undefined)
| Bid | 3.19 |
| Market Cap | 80.21M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -2.28 |
| PE Ratio (ttm) | -1.43 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | 3.22 |
| Volume | 332,432 |
| Avg. Volume (20D) | 351,155 |
| Open | 3.09 |
| Previous Close | 3.00 |
| Day's Range | 3.01 - 3.27 |
| 52-Week Range | 1.21 - 3.81 |
| Beta | undefined |
About AADI
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR path...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 16, 2018
Employees 53
Stock Exchange NASDAQ
Ticker Symbol AADI
Website https://aadibio.com
Analyst Forecast
According to 3 analyst ratings, the average rating for AADI stock is "Hold." The 12-month stock price forecast is $1.75, which is a decrease of -46.15% from the latest price.
Buy 0.00%
Hold 100.00%
Sell 0.00%
Next Earnings Release
Aadi Bioscience Inc. is scheduled to release its earnings on Mar 12, 2025,
before market opens.
Analysts project revenue of $7.37M, reflecting a 16.50% YoY growth and earnings per share of -0.34, making a -43.33% decrease YoY.
Analysts project revenue of $7.37M, reflecting a 16.50% YoY growth and earnings per share of -0.34, making a -43.33% decrease YoY.
3 weeks ago ·
Source
+46.12%
Aadi Bioscience shares are trading higher after th...
Unlock content with
Pro Subscription
4 months ago ·
Source
-4.32%
Aadi Bioscience shares are trading lower after the company announced an analysis by the Independent Data Monitoring Committee demonstrated that the study was unlikely to exceed an efficacy threshold necessary to support an accelerated approval. The company will pause new enrollment and is reducing its Research & Development workforce by 80%.
